Cellectis SA (CLLS) has released an update.
Cellectis, a clinical-stage biotech company, has announced a breakthrough in Nature Communications with a non-viral gene therapy approach for treating Sickle Cell Disease (SCD). Their proprietary TALEN technology enables precise HBB gene correction in patient-derived stem cells, showing promise in preclinical models with over 50% normal hemoglobin expression and successful engraftment in mice. This innovation could potentially offer a new treatment alternative for SCD, a disease affecting millions worldwide.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
